« Return to News | CROs/Service Providers | Drug Sponsors

PRA, Amgen collaborate on biosimilar development program

Wednesday, May 2, 2012 09:18 AM

PRA, a global CRO, has formed a strategic relationship with biotech Amgen for a series of phase III studies to develop several biosimilar drugs on a worldwide basis.

The agreement is intended to govern the entire anticipated scope of Amgen's global biosimilar portfolio and PRA will serve as the sole provider of CRO services for these studies.

"This agreement reflects and confirms PRA's commitment to providing full service support to our clients' development pipelines," said Kent Thoelke, PRA's executive vice president of scientific and medical affairs. "Our mission is to assist our clients across all phases of biotech drug development by combining therapeutic and operational expertise with local knowledge to help them meet their development goals.”

Thoelke added, “This relationship represents a key milestone in PRA's commitment to supporting our clients' biosimilar development programs. Amgen is a blue chip company and a world leader with a global reputation for excellence in bringing biologic therapies to patients with grievous illnesses. PRA has a strong track record in executing our clients' global registration trials and helping to bring new drugs to market.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.